UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2017
Commission file number: 001-36621
FOAMIX PHARMACEUTICALS LTD.
(Translation of registrant's name into English)
2 Holzman Street, Weizmann Science Park
Rehovot, Israel
(Address of principal executive office)
_____________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
S
Form 40-F
£
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
£
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
£
CONTENTS
This report on Form 6-K of the registrant consists of (i) a press release issued by the registrant on March 27, 2017, and (ii) a presentation dated March 2017, each of which is attached hereto as an exhibit and incorporated by reference herein.
The information contained in this Form 6-K is incorporated by reference into (i) the registration statement on Form S-8 (number 333-199486) of the registrant, filed with the Securities and Exchange Commission (the "SEC"), as amended by the post-effective registration statement on Form S-8 POS filed February 5, 2016, (ii) the registration statement on Form S-8 (number 333-209403) of the registrant, filed with the SEC, and (iii) the registration statement on Form F-3 (333-216224) of the registrant, filed with the SEC on February 24, 2017, in each case to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
Exhibits
|
99.1
|
Press release: Foamix Reports Topline Results from Phase 3 Trials for FMX101 in Patients with Acne
|
|
99.2
|
Presentation: FMX101 Topical 4% Minocycline Foam for Moderate-to-Severe Acne – Phase 3 Results
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
FOAMIX PHARMACEUTICALS LTD.
(Registrant)
|
|
|
|
|
|
|
|
|
By:
|
/s/ Ilan Hadar
|
|
|
|
|
Name: Ilan Hadar
|
|
|
|
|
Title: Chief Financial Officer
|
|
|
|
|
|
|
Date: March 27, 2017
2